[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.148.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
April 1973

Antithymocyte Globulin in Renal Transplant RecipientsA Clinical Trial

Author Affiliations

Ann Arbor, Mich
From the Section of General Surgery (Drs. Turcotte, Feduska, Haines, Freier, and Thompson) and departments of medicine (Dr. Mc Donald), microbiology (Dr. Johnson), and pathology (Dr. Gikas), University of Michigan Medical Center, Ann Arbor; and the Research Laboratories, the Upjohn Co., Kalamazoo, Mich (Dr. Morrell).

Arch Surg. 1973;106(4):484-488. doi:10.1001/archsurg.1973.01350160102016
Abstract

Thirty-six intrafamilial and 35 cadaveric transplants performed consecutively between June 1969 and March 1971 were prospectively randomized into a control group and one treated with horse antihuman thymocyte globulin (HATG). All histocompatible related allografts are functioning regardless of whether HATG was used. Two year life-table survival for incompatible related grafts is 85.7% for HATG treated vs 58.4% for concurrent control grafts, while there was no difference in transplant survival of cadaveric grafts whether or not HATG was administered. Significantly fewer rejection episodes occurred in HATG cadaveric grafts. No differences in renal function, renal histologic findings, infections and other complications, or steroid requirements were noted when HATG-treated recipients were compared with control patients.

×